Jesus G Berdeja

21PUBLICATIONS
141CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsGene and molecular therapyClinical social work practice
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jul 22, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

|Jun 03, 2026
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

|Apr 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Doris K Hansen, Danai Dima, Hira Mian

|Jan 21, 2026
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Melissa Alsina, Nina Shah, Sundar Jagannath

|Jun 09, 2025
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Sheri Skerget, Daniel Penaherrera, Ajai Chari

|Jun 03, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Sundar Jagannath, Thomas G Martin, Yi Lin

Pageof 4

Frequent Collaborators

7 joint publications

Sundar Jagannath

6 joint publications

Yi Lin

5 joint publications

Saad Z Usmani

4 joint publications

Nikhil C Munshi